problem is... we don't know what BIOA considers to be "lowball."
All our number crunchers and valuation experts put this deal at $150M to $350M and most thought those were reasonable numbers when you consider all the variables.
What if BIOA considers $500M a lowball offer? It's considerably more than shareholder estimations, but probably less than the company desires.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.